ATE459357T1 - Kombinationen zur behandlung von multiplem myelom - Google Patents

Kombinationen zur behandlung von multiplem myelom

Info

Publication number: ATE459357T1
Authority: AT; Austria
Prior art keywords: methods; administration; disclosed; therapy; combinations
Prior art date: 2002-05-17

Application number

AT03728969T

Other languages

English (en)

Inventor

Jerome B Zeldis

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2003-05-16

Publication date

2010-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29553516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE459357(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-16 Application filed by Celgene Corp filed Critical Celgene Corp

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE459357T1 publication Critical patent/ATE459357T1/de

Links

208000034578 Multiple myelomas Diseases 0.000 title 1
206010035226 Plasma cell myeloma Diseases 0.000 title 1
238000000034 method Methods 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 2
230000002519 immonomodulatory effect Effects 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
238000001815 biotherapy Methods 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000001794 hormone therapy Methods 0.000 abstract 1
238000009169 immunotherapy Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Dermatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)

AT03728969T 2002-05-17 2003-05-16 Kombinationen zur behandlung von multiplem myelom ATE459357T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38084202P	2002-05-17	2002-05-17
US42460002P	2002-11-06	2002-11-06
PCT/US2003/015470 WO2003097052A2 (en)	2002-05-17	2003-05-16	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases

Publications (1)

Publication Number	Publication Date
ATE459357T1 true ATE459357T1 (de)	2010-03-15

Family

ID=29553516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03728969T ATE459357T1 (de)	2002-05-17	2003-05-16	Kombinationen zur behandlung von multiplem myelom

Country Status (19)

Country	Link
EP (9)	EP2105135B1 (de)
JP (8)	JP2005530784A (de)
KR (2)	KR100793564B1 (de)
CN (13)	CN103393695A (de)
AT (1)	ATE459357T1 (de)
AU (1)	AU2003234626B2 (de)
CA (10)	CA2752124A1 (de)
CY (3)	CY1110013T1 (de)
DE (1)	DE60331537D1 (de)
DK (1)	DK1505973T3 (de)
ES (2)	ES2340027T3 (de)
IL (9)	IL165254A0 (de)
LU (1)	LU92642I2 (de)
MX (1)	MXPA04011311A (de)
NZ (5)	NZ536907A (de)
PT (2)	PT2105135E (de)
SI (1)	SI1505973T1 (de)
WO (1)	WO2003097052A2 (de)
ZA (3)	ZA200503656B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7320991B2 (en)	2001-02-27	2008-01-22	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health	Analogs of thalidomide as potential angiogenesis inhibitors
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2752124A1 (en) *	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
NZ540186A (en) *	2002-10-31	2008-03-28	Celgene Corp	Composition for the treatment of macular degeneration
US7785601B2 (en) *	2002-12-31	2010-08-31	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
WO2005016326A2 (en) *	2003-07-11	2005-02-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Analogs of thalidomide as potential angiogenesis inhibitors
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7973057B2 (en)	2003-09-17	2011-07-05	The United States Of America As Represented By The Department Of Health And Human Services	Thalidomide analogs
US8952895B2 (en)	2011-06-03	2015-02-10	Apple Inc.	Motion-based device operations
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20060109979A (ko) *	2003-12-02	2006-10-23	셀진 코포레이션	혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CA2601278C (en)	2004-03-17	2014-06-10	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
CA2560221C (en) *	2004-03-22	2010-12-07	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
AU2004319758A1 (en) *	2004-04-14	2005-11-24	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
CN101098694A (zh) *	2004-11-12	2008-01-02	细胞基因公司	使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物
ZA200704890B (en) *	2004-11-23	2008-09-25	Celgene Corp	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
PL1928492T3 (pl) *	2005-09-01	2011-09-30	Celgene Corp	Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
WO2007072225A2 (en) *	2005-12-01	2007-06-28	Medical Prognosis Institute	Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007120669A1 (en)	2006-04-13	2007-10-25	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Tetrahalogenated compounds useful as inhibitors of angiogenesis
CA2652888A1 (en) *	2006-05-26	2007-12-06	Celgene Corporation	Methods and compositions using immunomodulatory compounds in combination therapy
CL2007002218A1 (es) *	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AU2007281684C1 (en) *	2006-08-07	2013-12-19	Abbvie Biotherapeutics Inc.	Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
AP2009004834A0 (en) *	2006-10-19	2009-04-30	Celgene Corp	Methods and compositions using immunomodulatory c ompounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
RU2348420C2 (ru) *	2007-04-17	2009-03-10	ФГУ Ростовский научно-исследовательский онкологический институт Росздрава	Способ лечения местно-распространенного рака легкого
NZ599825A (en) *	2007-09-28	2014-10-31	Anthrogenesis Corp	Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
UA104579C2 (uk) *	2007-12-10	2014-02-25	Байокрист Фармасьютикалз, Инк.	Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
JP2011510983A (ja) *	2008-01-29	2011-04-07	セルジーンコーポレイション	Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
RU2398525C1 (ru) *	2009-03-25	2010-09-10	Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий"	Способ лечения рака легкого
CN101696205B (zh)	2009-11-02	2011-10-19	南京卡文迪许生物工程技术有限公司	3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
US8841325B2 (en) *	2009-11-24	2014-09-23	Celgene Corporation	Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells
PL3202460T3 (pl)	2010-02-11	2019-12-31	Celgene Corporation	Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
KR20130038838A (ko) *	2010-03-12	2013-04-18	셀진 코포레이션	레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
US10426740B1 (en)	2010-08-18	2019-10-01	Avm Biotechnology, Llc	Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US20120045435A1 (en) *	2010-08-18	2012-02-23	Theresa Deisher	Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2012062366A1 (en) *	2010-11-11	2012-05-18	Ingo Schmidt-Wolf	Compositions comprising wnt inhibitors for treating cancer
US8927725B2 (en)	2011-12-02	2015-01-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thio compounds
EP2892537A1 (de) *	2012-09-10	2015-07-15	Celgene Corporation	Verfahren zur behandlung von lokal fortgeschrittenem brustkrebs
BR112015025252A2 (pt) *	2013-04-02	2017-07-18	Celgene Corp	métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
GB201322626D0 (en) *	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
CN104231068A (zh) *	2014-01-27	2014-12-24	苏州发士达生物科技有限公司	人白细胞介素ii突变体及其应用
JP6616934B2 (ja) *	2014-05-22	2019-12-04	株式会社資生堂	レナリドミドの光学分割方法
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
DK3198035T3 (da)	2014-09-26	2023-01-30	Allarity Therapeutics Europe ApS	Fremgangsmåder til forudsigelse af medicinrespons
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
US20180014914A1 (en) *	2015-01-20	2018-01-18	Sreevatsan Raghavan	Self-illuminating cheek retractor
WO2016176675A2 (en) *	2015-04-30	2016-11-03	Nant Holdings Ip, Llc	Patient treatment via teratogenic pharmaceutical compounds
RS62352B1 (sr) *	2015-06-29	2021-10-29	Bristol Myers Squibb Co	Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera
WO2017070606A1 (en) *	2015-10-21	2017-04-27	Teclison Limited	Compositions and methods for immune-mediated cancer therapy
CN105388237B (zh) *	2015-12-28	2017-02-01	成都百裕金阁莱药业有限公司	阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法
US9725769B1 (en)	2016-10-07	2017-08-08	Oncology Venture ApS	Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en)	2016-12-30	2018-07-19	Allarity Therapeutics Europe ApS	Methods for predicting drug responsiveness in cancer patients
IL312367A (en)	2017-01-31	2024-06-01	Arvinas Operations Inc	Cereblon ligands and bifunctional compounds comprising the same
EP3490605B1 (de)	2017-04-01	2023-06-07	AVM Biotechnology, LLC	Ersatz von zytotoxischer vorbehandlung vor einer zellulären immuntherapie
MY206158A (en)	2017-05-24	2024-12-02	Novartis Ag	Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2019081749A1 (en) *	2017-10-26	2019-05-02	Synbias Pharma Ag	IMMEDIATE RELEASE FORMULATIONS OF LENALIDOMIDE
FI3784663T3 (fi)	2018-04-23	2023-10-06	Celgene Corp	Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
KR102718800B1 (ko) *	2018-05-23	2024-10-18	셀진 코포레이션	다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
KR20210056397A (ko) *	2018-09-07	2021-05-18	메드샤인 디스커버리 아이엔씨.	삼환식 치환 피페리딘 디온계 화합물
EP3488851A1 (de)	2018-10-03	2019-05-29	AVM Biotechnology, LLC	Immunoablative therapien
CN114502176A (zh) *	2019-10-04	2022-05-13	达纳-法伯癌症研究所股份有限公司	作为zeta链相关蛋白激酶70(zap70)激动剂的免疫调节性酰亚胺药物及其用途
PL4048278T3 (pl)	2019-10-21	2024-03-18	Celgene Corporation	Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu
IL292305A (en) *	2019-10-21	2022-06-01	Celgene Corp	Methods for the treatment of hematological cancer and the use of associated biomarkers for 2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isodonyl 1,3-discussion
AU2020405129A1 (en)	2019-12-19	2022-06-23	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of androgen receptor

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3228601A (en)	1964-02-20	1966-01-11	Monarch Marking Systems Inc	Controls for marking machine
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US5001116A (en)	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US4994443A (en)	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja)	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en)	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US6114355A (en)	1993-03-01	2000-09-05	D'amato; Robert	Methods and compositions for inhibition of angiogenesis
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE122007000079I2 (de)	1996-07-24	2010-08-12	Celgene Corp	Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en)	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
NZ334148A (en)	1996-08-12	2001-12-21	Celgene Corp	3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
ATE493983T1 (de) *	1996-11-05	2011-01-15	Childrens Medical Center	Thalidomide und dexamethason für die behandlung von tumors
US5874448A (en)	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
WO2000059473A1 (en) *	1999-04-01	2000-10-12	Inex Pharmaceuticals Corp.	Compositions and methods for treating lymphoma
HUP0204562A2 (hu) *	2000-03-17	2003-04-28	Cell Therapeutics, Inc.	Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények
AU2001261474B2 (en) *	2000-05-15	2006-03-09	Celgene Corporation	Compositions and methods for the treatment of cancer
US6458810B1 (en) *	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
ATE374609T1 (de) *	2000-11-30	2007-10-15	Childrens Medical Center	Synthese von 4-aminothalidomid enantiomeren
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2752124A1 (en)	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer

2003
- 2003-05-16 CA CA2752124A patent/CA2752124A1/en not_active Abandoned
- 2003-05-16 EP EP09008756.0A patent/EP2105135B1/de not_active Revoked
- 2003-05-16 CN CN2013103449770A patent/CN103393695A/zh not_active Withdrawn
- 2003-05-16 MX MXPA04011311A patent/MXPA04011311A/es active IP Right Grant
- 2003-05-16 CN CN038168995A patent/CN1697655B/zh not_active Expired - Lifetime
- 2003-05-16 PT PT90087560T patent/PT2105135E/pt unknown
- 2003-05-16 PT PT03728969T patent/PT1505973E/pt unknown
- 2003-05-16 CA CA2727824A patent/CA2727824A1/en not_active Abandoned
- 2003-05-16 CN CN2011102561581A patent/CN102335173A/zh active Pending
- 2003-05-16 NZ NZ536907A patent/NZ536907A/en not_active IP Right Cessation
- 2003-05-16 CA CA2794060A patent/CA2794060C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201110256752.0A patent/CN102379874B/zh not_active Expired - Lifetime
- 2003-05-16 JP JP2004505051A patent/JP2005530784A/ja active Pending
- 2003-05-16 EP EP09004756A patent/EP2087891A3/de not_active Withdrawn
- 2003-05-16 CA CA2727830A patent/CA2727830C/en not_active Expired - Lifetime
- 2003-05-16 AT AT03728969T patent/ATE459357T1/de active
- 2003-05-16 DK DK03728969.1T patent/DK1505973T3/da active
- 2003-05-16 EP EP10185504A patent/EP2316455A1/de not_active Withdrawn
- 2003-05-16 KR KR1020047018587A patent/KR100793564B1/ko not_active Expired - Lifetime
- 2003-05-16 SI SI200331793T patent/SI1505973T1/sl unknown
- 2003-05-16 IL IL16525403A patent/IL165254A0/xx unknown
- 2003-05-16 CN CN201310344609.6A patent/CN103494817A/zh not_active Withdrawn
- 2003-05-16 NZ NZ563281A patent/NZ563281A/en not_active IP Right Cessation
- 2003-05-16 ES ES03728969T patent/ES2340027T3/es not_active Expired - Lifetime
- 2003-05-16 WO PCT/US2003/015470 patent/WO2003097052A2/en not_active Ceased
- 2003-05-16 CA CA2794297A patent/CA2794297A1/en not_active Abandoned
- 2003-05-16 CA CA2672000A patent/CA2672000C/en not_active Expired - Lifetime
- 2003-05-16 CN CN201410690665.XA patent/CN104606193A/zh not_active Withdrawn
- 2003-05-16 EP EP12158938.6A patent/EP2561874A3/de not_active Withdrawn
- 2003-05-16 EP EP10177056A patent/EP2272513A1/de not_active Withdrawn
- 2003-05-16 CA CA2752127A patent/CA2752127A1/en not_active Abandoned
- 2003-05-16 CA CA2752122A patent/CA2752122A1/en not_active Abandoned
- 2003-05-16 ES ES09008756.0T patent/ES2521672T3/es not_active Expired - Lifetime
- 2003-05-16 CA CA2476983A patent/CA2476983C/en not_active Expired - Lifetime
- 2003-05-16 CA CA2752140A patent/CA2752140A1/en not_active Abandoned
- 2003-05-16 KR KR1020067020849A patent/KR100822149B1/ko not_active Expired - Fee Related
- 2003-05-16 NZ NZ584663A patent/NZ584663A/en not_active IP Right Cessation
- 2003-05-16 CN CN201310344594.3A patent/CN103393681B/zh not_active Expired - Lifetime
- 2003-05-16 AU AU2003234626A patent/AU2003234626B2/en not_active Expired
- 2003-05-16 EP EP03728969A patent/EP1505973B1/de not_active Revoked
- 2003-05-16 CN CN201110257161.5A patent/CN102342938B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP14189022.8A patent/EP2915533B1/de not_active Revoked
- 2003-05-16 NZ NZ549175A patent/NZ549175A/en not_active IP Right Cessation
- 2003-05-16 CN CN2011102571780A patent/CN102429908A/zh active Pending
- 2003-05-16 NZ NZ572388A patent/NZ572388A/en not_active IP Right Cessation
- 2003-05-16 DE DE60331537T patent/DE60331537D1/de not_active Expired - Lifetime
- 2003-05-16 CN CN201310343756.1A patent/CN103495169B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP09008775A patent/EP2105136A3/de not_active Withdrawn
- 2003-05-16 CN CN2011102566053A patent/CN102302494A/zh active Pending
- 2003-05-16 EP EP10177041A patent/EP2272512A1/de not_active Withdrawn
- 2003-05-16 CN CN2006101504843A patent/CN1981761B/zh not_active Expired - Fee Related
- 2003-11-06 CN CNA2003801083980A patent/CN1735415A/zh active Pending
- 2003-11-06 ZA ZA200503656A patent/ZA200503656B/xx unknown
2004
- 2004-11-16 IL IL165254A patent/IL165254A/en active IP Right Grant
- 2004-11-22 ZA ZA200409388A patent/ZA200409388B/xx unknown
- 2004-11-22 ZA ZA200409387A patent/ZA200409387B/en unknown
2006
- 2006-10-19 IL IL178748A patent/IL178748A/en active IP Right Grant
- 2006-10-19 IL IL178746A patent/IL178746A0/en unknown
- 2006-10-19 IL IL178747A patent/IL178747A/en active IP Right Grant
- 2006-10-19 IL IL178745A patent/IL178745A/en active Protection Beyond IP Right Term
- 2006-10-24 JP JP2006288966A patent/JP2007008966A/ja active Pending
2009
- 2009-05-13 JP JP2009116367A patent/JP5839770B2/ja not_active Expired - Lifetime
- 2009-05-13 JP JP2009116363A patent/JP2009191072A/ja not_active Withdrawn
- 2009-05-26 IL IL198978A patent/IL198978A/en active IP Right Grant
2010
- 2010-04-23 CY CY20101100363T patent/CY1110013T1/el unknown
2012
- 2012-05-10 IL IL219732A patent/IL219732A0/en unknown
- 2012-12-14 JP JP2012273326A patent/JP5830005B2/ja not_active Expired - Lifetime
2013
- 2013-02-28 JP JP2013038222A patent/JP2013126999A/ja not_active Withdrawn
2014
- 2014-11-27 CY CY20141100987T patent/CY1115782T1/el unknown
2015
- 2015-01-27 LU LU92642C patent/LU92642I2/xx unknown
- 2015-02-06 CY CY2015003C patent/CY2015003I2/el unknown
- 2015-06-23 JP JP2015125342A patent/JP6194335B2/ja not_active Expired - Lifetime
2016
- 2016-03-22 IL IL244727A patent/IL244727A0/en unknown
2017
- 2017-05-12 JP JP2017095838A patent/JP2017132817A/ja active Pending

Also Published As

Publication number	Publication date
EP2915533A1 (de)	2015-09-09
CA2752124A1 (en)	2003-11-27
CA2727830C (en)	2014-09-16
EP2272513A1 (de)	2011-01-12
EP2561874A2 (de)	2013-02-27
JP2007008966A (ja)	2007-01-18
AU2003234626B2 (en)	2006-03-09
CA2476983C (en)	2011-01-25
CN103495169A (zh)	2014-01-08
NZ549175A (en)	2007-12-21
EP2915533B1 (de)	2017-09-13
CN104606193A (zh)	2015-05-13
JP5830005B2 (ja)	2015-12-09
CA2794060A1 (en)	2003-11-27
CN102342938B (zh)	2014-08-20
JP2015187156A (ja)	2015-10-29
DK1505973T3 (da)	2010-05-31
JP2013126999A (ja)	2013-06-27
ZA200409387B (en)	2006-06-28
EP2087891A2 (de)	2009-08-12
CN1697655B (zh)	2013-09-18
IL178748A0 (en)	2007-02-11
KR20060110014A (ko)	2006-10-23
AU2003234626C1 (en)	2003-12-02
CY1115782T1 (el)	2015-12-09
IL219732A0 (en)	2012-06-28
JP2005530784A (ja)	2005-10-13
IL244727A0 (en)	2016-05-01
CY2015003I1 (el)	2015-12-09
IL178747A0 (en)	2007-02-11
KR20050010815A (ko)	2005-01-28
CA2752140A1 (en)	2003-11-27
CN103494817A (zh)	2014-01-08
WO2003097052A3 (en)	2003-12-18
JP2017132817A (ja)	2017-08-03
JP6194335B2 (ja)	2017-09-06
IL178745A (en)	2012-06-28
MXPA04011311A (es)	2005-02-14
CA2727824A1 (en)	2003-11-27
IL198978A (en)	2011-08-31
EP2105135A2 (de)	2009-09-30
EP1505973A4 (de)	2006-05-17
HK1134019A1 (en)	2010-04-16
CN102335173A (zh)	2012-02-01
EP2316455A1 (de)	2011-05-04
KR100793564B1 (ko)	2008-01-14
PT1505973E (pt)	2010-05-21
CN102379874A (zh)	2012-03-21
JP2013049734A (ja)	2013-03-14
IL178748A (en)	2013-10-31
EP1505973A2 (de)	2005-02-16
AU2003234626A1 (en)	2003-12-02
CN102302494A (zh)	2012-01-04
JP2009173683A (ja)	2009-08-06
SI1505973T1 (sl)	2010-06-30
EP2561874A3 (de)	2013-09-04
CN102429908A (zh)	2012-05-02
CN103393681B (zh)	2017-04-12
JP2009191072A (ja)	2009-08-27
CN102379874B (zh)	2016-08-17
CA2476983A1 (en)	2003-11-27
EP2272512A1 (de)	2011-01-12
DE60331537D1 (de)	2010-04-15
CN102342938A (zh)	2012-02-08
CY2015003I2 (el)	2015-12-09
NZ563281A (en)	2009-05-31
CN1981761B (zh)	2011-10-12
EP2087891A3 (de)	2010-01-27
EP2105136A2 (de)	2009-09-30
HK1072180A1 (en)	2005-08-19
PT2105135E (pt)	2015-02-06
IL165254A0 (en)	2005-12-18
CN103393695A (zh)	2013-11-20
ZA200503656B (en)	2009-02-25
NZ572388A (en)	2010-05-28
EP1505973B1 (de)	2010-03-03
CN103495169B (zh)	2016-06-22
KR100822149B1 (ko)	2008-04-15
CA2752122A1 (en)	2003-11-27
LU92642I2 (fr)	2015-04-24
EP2105135B1 (de)	2014-10-22
CN1981761A (zh)	2007-06-20
CN1697655A (zh)	2005-11-16
ZA200409388B (en)	2006-05-31
ES2521672T3 (es)	2014-11-13
ES2340027T3 (es)	2010-05-28
EP2105136A3 (de)	2010-01-27
IL178747A (en)	2015-06-30
IL178746A0 (en)	2007-02-11
CN103393681A (zh)	2013-11-20
IL178745A0 (en)	2007-02-11
JP5839770B2 (ja)	2016-01-06
CA2794060C (en)	2017-08-22
EP2105135A3 (de)	2010-02-10
CA2672000C (en)	2011-11-29
CA2752127A1 (en)	2003-11-27
CA2727830A1 (en)	2003-11-27
NZ584663A (en)	2011-09-30
IL165254A (en)	2013-03-24
NZ536907A (en)	2006-10-27
CY1110013T1 (el)	2015-01-14
CN1735415A (zh)	2006-02-15
CA2794297A1 (en)	2003-11-27
CA2672000A1 (en)	2003-11-27
WO2003097052A2 (en)	2003-11-27
HK1104968A1 (en)	2008-02-01

Legal Events

Date

Code

Title

Description

2010-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1505973

Country of ref document: EP

Publication	Publication Date	Title
ATE459357T1 (de)	2010-03-15	Kombinationen zur behandlung von multiplem myelom
MXPA05012155A (es)	2006-02-22	Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
TW200500355A (en)	2005-01-01	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MX2007005570A (es)	2007-07-09	Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
UA94097C2 (ru)	2011-04-11	Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
CY1108932T1 (el)	2014-07-02	Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
TW200501945A (en)	2005-01-16	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
TW200611695A (en)	2006-04-16	Pyrrolopyridine derivatives
MX2008008556A (es)	2008-09-26	Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
ATE482217T1 (de)	2010-10-15	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE412411T1 (de)	2008-11-15	Pmcol zur behandlung von prostatakrebs
BRPI0419229A (pt)	2007-12-18	derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
TW200603791A (en)	2006-02-01	Compounds and compositions as cathepsin S inhibitors